CHMP fandt, at vurderingen gav anledning til betænkeligheder vedrørende risk/ benefit- forholdet for piroxicam og underrettede Europa- Kommissionen herom.
The CHMP considered that the assessment raised concerns on the benefit/ risk balance of piroxicam and informed the European Commission accordingly.